Last reviewed · How we verify
COVID-globulin
COVID-globulin is a Small molecule drug developed by Microgen. It is currently in Phase 2 development. Also known as: Anti-coronavirus human immunoglobulin.
COVID-globulin, also known as Vaccinia Immune Globulin, is an intravenous immunoglobulin therapy used to treat various conditions, including Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure, Coronary Artery Disease, and Diabetes Mellitus. The exact mechanism of COVID-globulin is unknown, as per the available information.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | COVID-globulin |
|---|---|
| Also known as | Anti-coronavirus human immunoglobulin |
| Sponsor | Microgen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 (PHASE2)
- RECOVER-AUTONOMIC Platform Protocol (PHASE2)
- Outpatient Treatment With Anti-Coronavirus Immunoglobulin (PHASE3)
- COVID-19 International Drug Pregnancy Registry
- LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions
- Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study) (PHASE2)
- RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG) (PHASE2)
- COVID-19 VaccinE Response in Rheumatology Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COVID-globulin CI brief — competitive landscape report
- COVID-globulin updates RSS · CI watch RSS
- Microgen portfolio CI
Frequently asked questions about COVID-globulin
What is COVID-globulin?
Who makes COVID-globulin?
Is COVID-globulin also known as anything else?
What development phase is COVID-globulin in?
Related
- Manufacturer: Microgen — full pipeline
- Also known as: Anti-coronavirus human immunoglobulin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing